{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:27Z","timestamp":1792839627082,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHN 1626\/1-1"],"award-info":[{"award-number":["SCHN 1626\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["403224013 \\u2013 CRC 1382"],"award-info":[{"award-number":["403224013 \\u2013 CRC 1382"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["802544"],"award-info":[{"award-number":["802544"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01069"],"award-info":[{"award-number":["2019-01069"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jhepr.2022.100561","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T23:57:45Z","timestamp":1660780665000},"page":"100561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-7737","authenticated-orcid":false,"given":"Peder Rust\u00f8en","family":"Braadland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0047-3794","authenticated-orcid":false,"given":"Kai Markus","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-6241","authenticated-orcid":false,"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Molinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"L\u00f6vgren-Sandblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-0339","authenticated-orcid":false,"given":"Marcus","family":"Henricsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Hemming","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1493-2303","authenticated-orcid":false,"given":"Mette","family":"Vesterhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-8096","authenticated-orcid":false,"given":"Johannes Roksund","family":"Hov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-3085","authenticated-orcid":false,"given":"Hanns-Ulrich","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100561_bib1","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100561_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100561_bib3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100561_bib4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100561_bib5","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2017.01.019","article-title":"Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis","volume":"66","author":"Vesterhus","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100561_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0009-8981(96)06305-X","article-title":"Hepatic levels of bile acids in end-stage chronic cholestatic liver disease","volume":"251","author":"Fischer","year":"1996","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhepr.2022.100561_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2011.10.025","article-title":"Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study","volume":"44","author":"Trottier","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100561_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep.31652","article-title":"Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation","volume":"74","author":"Mousa","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100561_bib9","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"de Vries","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100561_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100561_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100561_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0014-5793(91)80688-Y","article-title":"The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man","volume":"284","author":"Axelson","year":"1991","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhepr.2022.100561_bib13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","author":"Schneider","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhepr.2022.100561_bib14","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D\u2019Amato","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2022.100561_bib15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhepr.2022.100561_bib16","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.4045\/tidsskr.09.1106","article-title":"[Liver transplantation in Norway through 25 years]","volume":"129","author":"Scholz","year":"2009","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.jhepr.2022.100561_bib17","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/TXD.0000000000000548","article-title":"Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway","volume":"1","author":"Andersen","year":"2015","journal-title":"Transpl Direct"},{"key":"10.1016\/j.jhepr.2022.100561_bib18","series-title":"rms: regression modeling strategies","author":"Harrell","year":"2021"},{"key":"10.1016\/j.jhepr.2022.100561_bib19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2796.2011.02466.x","article-title":"Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19","volume":"270","author":"Galman","year":"2011","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jhepr.2022.100561_bib20","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100561_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12072-016-9769-7","article-title":"Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge","volume":"11","author":"Zweers","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100561_bib22","article-title":"Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100561_bib23","article-title":"Dysregulation of circulating FGF19 and bile acids in primary biliary cholangitis-autoimmune hepatitis overlap syndrome","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhepr.2022.100561_bib24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100561_bib25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100561_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100561_bib27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2018.06.038","article-title":"An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers","volume":"155","author":"Al-Khaifi","year":"2018","journal-title":"Gastroenterology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:06:20Z","timestamp":1778904380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2589555922001331"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100561","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100561"}}